FY2025 · period end Dec '25 · from the 10-K filed Feb 6, 2026
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $9.89B |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 8-K | 0000875045-26-000068 | Jul 1, 2026 | Jul 1, 2026 | Jul 1, 2026 20:08 UTC | EDGAR |
| 8-K | 0000950157-26-000700 | Jun 9, 2026 | Jun 10, 2026 | Jun 10, 2026 20:54 UTC | EDGAR |
| 8-K | 0001193125-26-222908 | May 14, 2026 | May 14, 2026 | May 14, 2026 12:31 UTC | EDGAR |
| 8-K | 0000875045-26-000042 | Apr 29, 2026 | Apr 29, 2026 | Apr 29, 2026 10:05 UTC | EDGAR |
| 10-Q | 0000875045-26-000045 | Mar 31, 2026 | Apr 29, 2026 | Apr 29, 2026 10:40 UTC | EDGAR |
| 8-K | 0000875045-26-000039 | Apr 6, 2026 | Apr 6, 2026 | Apr 6, 2026 10:31 UTC | EDGAR |
| 8-K | 0001193125-26-134889 | Mar 31, 2026 | Mar 31, 2026 | Mar 31, 2026 21:03 UTC | EDGAR |
| 8-K | 0000950157-26-000280 | Mar 11, 2026 | Mar 11, 2026 | Mar 11, 2026 21:28 UTC | EDGAR |
Direct links to SEC EDGAR. BIIB has additional filings available on the SEC site.
Figures a later SEC filing revised from what was first reported. Each diff compares the same XBRL tag across two filings — both linked, so you can check it yourself.
Net Cash Provided by (Used in) Operating Activities·FY 2015
Notable restatementwas$3.7B
Revised up in a 10-K. Any P/OCF built on the original was 5.2% too high.
Net Cash Provided by (Used in) Operating Activities·Q1 2016
Notable restatementwas$963.4M
Revised up in a 10-Q. Any P/OCF built on the original was 5.2% too high.
Net Cash Provided by (Used in) Operating Activities·Q2 2016
Notable restatementwas$2B
Revised up in a 10-Q. Any P/OCF built on the original was 2.7% too high.
Net Cash Provided by (Used in) Operating Activities·Q3 2016
Notable restatementwas$2.9B
Revised up in a 10-Q. Any P/OCF built on the original was 2.0% too high.
Net Cash Provided by (Used in) Operating Activities·FY 2016
Minor restatementwas$4.5B
Revised up in a 10-K. Any P/OCF built on the original was 1.4% too high.
Long-term Debt·As of Dec 31, 2012
Major restatementwas$1B
Revised down in a 10-K.
BIIB is not the only one.
See every restatement we've found across the market — or get an alert the next time BIIB revises a number.
Restatements are detected by comparing every vintage of a fact across all of BIOGEN INC.'s filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows BIIB's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling BIOGEN INC. — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on BIIB yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on BIIB and publish the result to your public profile.
Get 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs| $9.84B |
| $10.17B |
| $10.98B |
| Gross Profit | $7.49B | $7.37B | $7.30B | $7.90B | $8.87B |
|---|
| Operating Income | — | — | — | — | $2.84B |
|---|
| Net Income | $1.29B | $1.63B | $1.16B | $3.05B | $1.56B |
|---|
| EPS (Diluted) | $8.79 | $11.18 | $7.97 | $20.87 | $10.40 |
|---|
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $29.44B | $28.05B | $26.84B | $24.55B | $23.88B |
| Total Liabilities | $11.18B | $11.33B | $12.05B | $11.17B | $12.92B |
| Stockholders' Equity | $18.26B | $16.72B | $14.80B | $13.39B | $10.96B |
| Cash & Equivalents | $3.01B | $2.38B | $1.05B | $3.42B | $2.26B |
| Total Debt | $6.57B | $6.57B | $7.22B | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | $2.20B | $2.88B | $1.55B | $1.38B | $3.64B |
| Capital Expenditures | $0.15B | $0.15B | $0.28B | $0.24B | $0.26B |
| Free Cash Flow | $2.05B | $2.72B | $1.27B | $1.14B | $3.38B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | 75.7% | 76.1% | 74.2% | 77.6% | 80.8% |
| Operating Margin | 0.3% | 0.3% | 0.2% | 0.3% | 0.3% |
| Net Margin | 0.1% | 0.2% | 0.1% | 0.3% | 0.1% |
| Return on Equity | 7.4% | 10.4% | 8.2% | 25.0% | 14.4% |
| Return on Assets | 4.5% | 5.9% | 4.5% | 12.6% | 6.4% |
| Debt / Equity | 0.36× | 0.39× | 0.49× | 0.47× | 0.57× |
